The regulatory landscape in the United Arab Emirates is undergoing significant transformation, with the country continuing to strengthen and centralise oversight of healthcare products through the **Emirates Drug Establishment> (EDE). Recent developments in 2026 highlight the UAE’s broader strategy to modernise healthcare regulation, improve efficiency, and position the country as a leading regional hub for healthcare innovation and market access. For medical device and pharm

International regulatory collaboration continues to play an increasingly important role in accelerating access to innovative healthcare technologies. In May 2026, the Health Sciences Authority of Singapore and China’s National Medical Products Administration signed a renewed Memorandum of Understanding (MOU), expanding their long-standing partnership in health product regulation. The updated agreement signals a stronger commitment to regulatory cooperation, innovation, and th

Saudi Arabia continues to enhance its regulatory framework for medical devices, with recent updates reinforcing the importance of accurate product classification and compliance. In early 2026, the Saudi Food and Drug Authority introduced updated product classification guidance, providing clearer requirements for how products are categorised and regulated within the Kingdom. This development reflects Saudi Arabia’s broader ambition to establish a more structured, transparent,

Regional regulatory collaboration in Southeast Asia is entering a new phase, as Medical Device Authority Malaysia and the Thai Food and Drug Administration officially announce the full implementation of their Medical Device Regulatory Reliance Programme in May 2026. This milestone follows the successful completion of a three-month pilot phase and represents a significant step toward regulatory harmonisation and more efficient market access across the ASEAN region. From Pilot

India continues to advance its regulatory framework for medical devices, with recent developments signalling a stronger and more structured approach to oversight, compliance, and market control. Under the leadership of the Central Drugs Standard Control Organisation, the country is expanding the scope of regulated medical devices while reinforcing licensing and compliance requirements across the sector. These changes are part of India’s broader effort to align with internatio

Vietnam continues to adjust its medical device regulatory framework in response to industry needs, with recent developments providing important relief for manufacturers navigating the country’s evolving system. In 2026, the Ministry of Health Vietnam confirmed the extension of medical device registration deadlines under Decree 07/2023, allowing companies additional time to maintain market access while regulatory processes continue to stabilise. This update reflects Vietnam’s

The regulatory landscape for medical devices in South Korea continues to evolve, with recent updates introducing a more flexible and structured approach to managing product changes. In March 2026, the Ministry of Food and Drug Safety proposed revisions to the Enforcement Rule of the Medical Devices Act, aiming to streamline how manufacturers handle post-approval changes to medical devices. This development reflects South Korea’s broader effort to enhance regulatory efficienc

Hong Kong is taking a significant step toward strengthening its medical device regulatory framework, with recent developments signalling a shift from a voluntary system toward more structured regulatory oversight. In March 2026, the Hong Kong Department of Health implemented Stage C of its medical device procurement framework, introducing new requirements that directly impact how medical devices are supplied to the public sector. This update marks an important evolution in H

China continues to position itself as one of the most attractive yet complex markets for medical device manufacturers, particularly in high-risk and innovation-driven segments such as ophthalmology. Recent insights into intraocular lens (IOL) registration highlight how the regulatory landscape is evolving under the National Medical Products Administration, with increasing emphasis on clinical evidence, product quality, and lifecycle compliance. As demand for advanced vision

The regulatory landscape for medical devices in the Philippines continues to evolve, reflecting the country’s commitment to strengthening healthcare systems and ensuring patient safety. Recent updates from the Food and Drug Administration of the Philippines highlight a growing focus on compliance, transparency, and alignment with international regulatory standards. These developments are shaping how medical device manufacturers approach market entry and ongoing regulatory obl

Recent regulatory developments in Thailand are drawing the attention of medical device manufacturers and regulatory professionals across Asia. The Thai Food and Drug Administration has announced an extension of the medical device annual reporting deadline, allowing companies additional time to comply with regulatory reporting obligations. The deadline has now been extended to 31 May 2026 , alongside revisions to sales reporting requirements for medical device companies oper

In March 2026, Singapore reached an important milestone in global health regulation. The World Health Organisation (WHO) announced that Singapore’s national regulator, the Health Sciences Authority (HSA), has achieved Maturity Level 4 (ML4) for its medical device regulatory system, the highest classification in WHO’s global benchmarking framework. This recognition positions Singapore as the first country in the world to reach the top regulatory maturity level specifically